These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 24614094)

  • 1. Anticancer drug development: moving away from the old habits.
    Ades F; Zardavas D; Aftimos P; Awada A
    Curr Opin Oncol; 2014 May; 26(3):334-9. PubMed ID: 24614094
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase 0 trials for anticancer drug development.
    Nat Rev Drug Discov; 2009 Jun; 8(6):442. PubMed ID: 19483703
    [No Abstract]   [Full Text] [Related]  

  • 3. Bypassing phase 1 trials in the cancer drug development paradigm: generally unwise and potentially dangerous.
    Markman M
    Cancer; 2010 Nov; 116(22):5116-8. PubMed ID: 20665504
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncology drug discovery: planning a turnaround.
    Toniatti C; Jones P; Graham H; Pagliara B; Draetta G
    Cancer Discov; 2014 Apr; 4(4):397-404. PubMed ID: 24706659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can attrition rates be reduced in cancer drug discovery?
    Moreno L; Pearson AD
    Expert Opin Drug Discov; 2013 Apr; 8(4):363-8. PubMed ID: 23373702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomedicine. Pharma firms push for sharing of cancer trial data.
    Bhattacharjee Y
    Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
    [No Abstract]   [Full Text] [Related]  

  • 8. Accelerated approval dust begins to settle.
    Mullard A
    Nat Rev Drug Discov; 2011 Oct; 10(11):797-8. PubMed ID: 22037027
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 10. Research outcomes and recommendations for the assessment of progression in cancer clinical trials.
    Bushnell W; Stone A
    J Biopharm Stat; 2013; 23(5):949-50. PubMed ID: 23957508
    [No Abstract]   [Full Text] [Related]  

  • 11. Regulatory Watch: Impact of breakthrough therapy designation on cancer drug development.
    Shea M; Ostermann L; Hohman R; Roberts S; Kozak M; Dull R; Allen J; Sigal E
    Nat Rev Drug Discov; 2016 Mar; 15(3):152. PubMed ID: 26931085
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical development of anticancer agents--a National Cancer Institute perspective.
    Marsoni S; Wittes R
    Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
    [No Abstract]   [Full Text] [Related]  

  • 13. [Development for and clinical trials of molecular targeting drugs].
    Takashima A; Fukuda H; Shibata T
    Gan To Kagaku Ryoho; 2010 May; 37(5):822-7. PubMed ID: 20524257
    [No Abstract]   [Full Text] [Related]  

  • 14. Developing drugs for pediatric malignancies.
    Adamson PC
    Clin Adv Hematol Oncol; 2013 Apr; 11(4):227-9. PubMed ID: 23604239
    [No Abstract]   [Full Text] [Related]  

  • 15. Cancer charity sees success re-prioritizing industry's shelved compounds.
    Mullard A
    Nat Rev Drug Discov; 2014 May; 13(5):319-21. PubMed ID: 24781536
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials and drug approvals continue to accelerate in China.
    Wang M
    Lancet Oncol; 2017 Jul; 18(7):855. PubMed ID: 28552212
    [No Abstract]   [Full Text] [Related]  

  • 17. Facilitating patient-centered cancer research and a new era of drug discovery.
    Niederhuber JE
    Oncologist; 2009 Apr; 14(4):311-2. PubMed ID: 19365096
    [No Abstract]   [Full Text] [Related]  

  • 18. Counterpoint: Data first.
    Golub T
    Nature; 2010 Apr; 464(7289):679. PubMed ID: 20360719
    [No Abstract]   [Full Text] [Related]  

  • 19. HSP90 inhibitors: current development and potential in cancer therapy.
    Sidera K; Patsavoudi E
    Recent Pat Anticancer Drug Discov; 2014 Jan; 9(1):1-20. PubMed ID: 23312026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.